High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: Potential role of Campath-1H in delaying immune reconstitution

Blood

Volumn 99, Issue 12, 2002, Pages 4357-4363

  Chakrabarti, Suparno ^a,b,c,d,e   Mackinnon, Stephen ^a,b,c,d,e   Chopra, Raj ^a,b,c,d,e   Kottaridis, Panagiotis D ^a,b,c,d,e   Peggs, Karl ^a,b,c,d,e   O'Gorman, Peter ^a,b,c,d,e   Chakraverty, Ronjon ^a,b,c,d,e   Marshall, Timothy ^a,b,c,d,e   Osman, Husam ^a,b,c,d,e   Mahendra, Premini ^a,b,c,d,e   Craddock, Charles ^a,b,c,d,e   Waldmann, Herman ^a,b,c,d,e   Hale, Geoff ^a,b,c,d,e   Fegan, Christopher D ^a,b,c,d,e   Yong, Kwee ^a,b,c,d,e   Goldstone, Anthony H ^a,b,c,d,e   Linch, David C ^a,b,c,d,e   Milligan, Donald W ^a,b,c,d,e  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN A; FLUDARABINE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; MELPHALAN;

ADULT; ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT VERSUS HOST REACTION; HIGH RISK POPULATION; HUMAN; HUMAN CELL; INCIDENCE; INFECTION RISK; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; STEM CELL TRANSPLANTATION; SURVIVAL; T LYMPHOCYTE; VIRUS REACTIVATION;

EID: 0037097836     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.12.4357     Document Type: Article

References (27)

1. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: Experience of European Bone Marrow Transplant Group
2. A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy
3. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation
4. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study
5. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection
6. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow recipients
7. + selected cells in patients with advanced malignancies: Severe immunodeficiency and related complications
8. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: Relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease
9. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: Risk factors, correlation with DNA load, and outcomes
10. Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation
11. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis
12. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
13. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
14. In vivo Campath-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
15. Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
16. Mixed chimerism: Preclinical studies and clinical applications
17. Non-myeloablative stem cell transplants
18. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation
19. Screening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: Analysis of potential risk factors for CMV infection
20. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: Effect of patient age and donor leukocyte infusions
21. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: A single-center experience
22. Risk factors for cytomegalovirus infection after human marrow transplantation
23. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation
24. GVHD and CMV antigenemia after allogeneic peripheral blood stem cell transplantation: Comparison between myeloablative and nonmyeloablative (min) conditioning regimens
25. Incidence of herpesvirus infections following nonmyeloablative allogeneic stem cell transplantation
26. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
27. Pharmacokinetics of Campath-1H in bone marrow transplant patients